|
Category: pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00 %
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 252.00 °C. @ 760.00 mm Hg
|
| Boiling Point: | 576.61 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 351.00 °F. TCC ( 177.40 °C. ) (est)
|
| logP (o/w): | 3.030 |
| Soluble in: |
| | water, 11.68 mg/L @ 25 °C (est) |
Organoleptic Properties:
| |
| Odor and/or flavor descriptions from others (if found). |
| |
| |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
oral-dog LD50 > 1000 mg/kg GASTROINTESTINAL: NAUSEA OR VOMITING Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
intraperitoneal-mouse LD50 372 mg/kg LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
BEHAVIORAL: ATAXIA
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
oral-mouse LD50 486 mg/kg LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
BEHAVIORAL: ATAXIA
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
intraperitoneal-rat LD50 885 mg/kg GASTROINTESTINAL: PERITONITIS
GASTROINTESTINAL: ULCERATION OR BLEEDING FROM SMALL INTESTINE
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
oral-rat LD50 418 mg/kg LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
GASTROINTESTINAL: ULCERATION OR BLEEDING FROM STOMACH
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 > 2000 mg/kg Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
subcutaneous-rat LD50 > 2000 mg/kg SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 4091, 1994.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | pharmaceuticals / chemical synthisis |
| Recommendation for finasteride usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for finasteride flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
| EPI System: | View |
| ClinicalTrials.gov: | search |
| Daily Med: | search |
| Chemical Carcinogenesis Research Information System: | Search |
| AIDS Citations: | Search |
| Cancer Citations: | Search |
| Toxicology Citations: | Search |
| Carcinogenic Potency Database: | Search |
| EPA ACToR: | Toxicology Data |
| EPA Substance Registry Services (SRS): | Registry |
| Laboratory Chemical Safety Summary : | 57363 |
| National Institute of Allergy and Infectious Diseases: | Data |
| WGK Germany: | 3 |
| | (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide |
| Chemidplus: | 0098319267 |
| RTECS: | CL5245000 for cas# 98319-26-7 |
References:
| | (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 57363 |
| Pubchem (sid): | 135016317 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert- | butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide |
Articles:
| Info: | Finasteride |
| PubMed: | Role of GABA-active neurosteroids in the efficacy of metyrapone against cocaine addiction. |
| PubMed: | The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. |
| PubMed: | Androgenetic alopecia (male pattern hair loss) in the United States: what treatments should primary care providers recommend? |
| PubMed: | New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line. |
| PubMed: | Effect of Phellius linteus water extract on benign prostatic hyperplasia. |
| PubMed: | Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride. |
| PubMed: | Current status of 5α-reductase inhibitors in prostate disease management. |
| PubMed: | Actos, slings, finasteride, and the vaccine compensation solution. |
| PubMed: | Role of 5α-reductase inhibitors in androgen-stimulated skin disorders. |
| PubMed: | Prevention strategies for prostate cancer. |
| PubMed: | Prostate, baldness drugs linked to sexual dysfunction. |
| PubMed: | [Prevention of uro-oncological diseases]. |
| PubMed: | Fraction of macroporous resin from Smilax china L. inhibits testosterone propionate-induced prostatic hyperplasia in castrated rats. |
| PubMed: | Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. |
| PubMed: | The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice. |
| PubMed: | [Primary prevention of urologic tumors: prostate cancer]. |
| PubMed: | 5-α reductase inhibitors and prostate cancer prevention: where do we turn now? |
| PubMed: | Effects of in utero exposure to D-004, a lipid extract from Roystonea regia fruits, in the male rat: a comparison with finasteride. |
| PubMed: | The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. |
| PubMed: | Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. |
| PubMed: | Update on the pathogenesis, genetics and medical treatment of patterned hair loss. |
| PubMed: | Types of hair loss and treatment options, including the novel low-level light therapy and its proposed mechanism. |
| PubMed: | Selenium, but not lycopene or vitamin E, decreases growth of transplantable dunning R3327-H rat prostate tumors. |
| PubMed: | Synergistic disruption of external male sex organ development by a mixture of four antiandrogens. |
| PubMed: | An overview on 5alpha-reductase inhibitors. |
| PubMed: | PCOS. |
| PubMed: | Hypersensitivity to intravenous ondansetron: a case report. |
| PubMed: | Preventing prostate cancer: new analyses put finasteride back on the map. |
| PubMed: | Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. |
| PubMed: | Anabolic effects of testosterone are preserved during inhibition of 5alpha-reductase. |
| PubMed: | [Chemoprevention of prostate cancer. Current status]. |
| PubMed: | Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. |
| PubMed: | Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. |
| PubMed: | Psychological effect, pathophysiology, and management of androgenetic alopecia in men. |
| PubMed: | Preventing diseases of the prostate in the elderly using hormones and nutriceuticals. |
| PubMed: | Clinical trials in cancer prevention: current results and perspectives for the future. |
| PubMed: | Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. |
| PubMed: | Common hair loss disorders. |
| PubMed: | The potential role of minoxidil in the hair transplantation setting. |
| PubMed: | Dietary supplement use in the Prostate Cancer Prevention Trial: implications for prevention trials. |
| PubMed: | Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents. |
| PubMed: | Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. |
| PubMed: | Bioequivalence study of finasteride. Determination in human plasma by high-pressure liquid chromatography coupled to tandem mass spectrometry. |
| PubMed: | Continuous haemodynamic monitoring in an unusual case of swallow induced syncope. |
| PubMed: | Planning and analysis of repeated measures at key time-points in clinical trials sponsored by pharmaceutical companies. |
| PubMed: | Study of the Food and Drug Administration files on Propecia: dosages, side effects, and recommendations. |
| PubMed: | Gone today, hair tomorrow? |
| PubMed: | Clinical pharmacokinetics and pharmacodynamics of finasteride. |
| PubMed: | [Chemoprevention of cancer of the prostate]. |
| PubMed: | New drugs from 1991-1992. |
| PubMed: | From the Food and Drug Administration. |
|